Breakthrough Therapy (BT) Designation - Global Strategic Business Report

Quick Summary:

The groundbreaking advancements in the Breakthrough Therapy (BT) Designation market have steadily unfolded a plethora of opportunities in the pharmaceutical industry, necessitating a deep understanding of the market trends to stay ahead in the competitive landscape. Our strategic market research report offers an expansive perspective into the dynamics of the BT Designation market, estimated to reach a substantial volume of US$371.1 Billion by 2030 from its current tally of US$86.3 Billion in 2022.

We meticulously analyze crucial market segments including Oncology, projected to reach an impressive US$125.5 Billion by the conclusion of the analysis period, and the Infectious Diseases segment carrying an adjusted growth potential of 17.3% CAGR for the next eight years. Our report also explores the geographic markets including the U.S., China, Japan, Canada, and Germany, outlining their potential growth rates and expected market sizes.

Our coverage also includes a comprehensive overview of the competitive landscape featuring key players like Abbvie, Acadia, Alexion, and others. Benefit from our online interactive peer-to-peer collaborative bespoke updates and comprehensive access to digital archives and our research platform. We also provide complimentary updates for a year to ensure you stay abreast with the evolving market trends.

Global Breakthrough Therapy (BT) Designation Market to Reach $371.1 Billion by 2030

The global market for Breakthrough Therapy (BT) Designation estimated at US$86.3 Billion in the year 2022, is projected to reach a revised size of US$371.1 Billion by 2030, growing at a CAGR of 20% over the analysis period 2022-2030. Oncology, one of the segments analyzed in the report, is projected to record 21.1% CAGR and reach US$125.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Infectious Diseases segment is readjusted to a revised 17.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $25.3 Billion, While China is Forecast to Grow at 19.2% CAGR

The Breakthrough Therapy (BT) Designation market in the U.S. is estimated at US$25.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$63.6 Billion by the year 2030 trailing a CAGR of 19.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.7% and 17% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 14.5% CAGR.

Select Competitors (Total 42 Featured) -

Abbvie
Acadia
Alexion
Amgen
AstraZeneca
BMS
Boehringer Ingelheim
Eisai
Eli Lilly
Exelixis

What's New?

Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to digital archives and Research Platform
Complimentary updates for one year

Frequently Asked Questions about the Global Market for Breakthrough Therapy (BT) Designation

What is the estimated value of the Global Market for Breakthrough Therapy (BT) Designation?

The Global Market for Breakthrough Therapy (BT) Designation was estimated to be valued at $86.3 Billion in 2022.

What is the growth rate of the Global Market for Breakthrough Therapy (BT) Designation?

The growth rate of the Global Market for Breakthrough Therapy (BT) Designation is 20.0%, with an estimated value of $371.1 Billion by 2030.

What is the forecasted size of the Global Market for Breakthrough Therapy (BT) Designation?

The Global Market for Breakthrough Therapy (BT) Designation is estimated to be worth $371.1 Billion by 2030.

Who are the key companies in the Global Market for Breakthrough Therapy (BT) Designation?

Key companies in the Global Market for Breakthrough Therapy (BT) Designation include Abbvie, Acadia, Alexion, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eisai, Eli Lilly and Exelixis.

Report Attribute	Details
No. of Pages	93
Published	September 2023
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 86.3 Billion
Forecasted Market Value ( USD ) by 2030	$ 371.1 Billion
Compound Annual Growth Rate	20.0%
Regions Covered	Global

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Breakthrough Therapy (BT) Designation - Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Breakthrough Therapy (BT) Designation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Breakthrough Therapy (BT) Designation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 5: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 6: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 9: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 12: World 16-Year Perspective for Rare Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for Pulmonary Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Pulmonary Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 15: World 16-Year Perspective for Pulmonary Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 18: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
Table 19: World Breakthrough Therapy (BT) Designation Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES

Breakthrough Therapy (BT) Designation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
Table 20: USA Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 21: USA Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 22: USA 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

CANADA

Table 23: Canada Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 24: Canada Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 25: Canada 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

JAPAN

Breakthrough Therapy (BT) Designation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 26: Japan Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 27: Japan Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 28: Japan 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

CHINA

Breakthrough Therapy (BT) Designation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
Table 29: China Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 30: China Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 31: China 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

EUROPE

Breakthrough Therapy (BT) Designation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 32: Europe Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 33: Europe Historic Review for Breakthrough Therapy (BT) Designation by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 34: Europe 16-Year Perspective for Breakthrough Therapy (BT) Designation by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
Table 35: Europe Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 36: Europe Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 37: Europe 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

FRANCE

Breakthrough Therapy (BT) Designation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
Table 38: France Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 39: France Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 40: France 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

GERMANY

Breakthrough Therapy (BT) Designation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 41: Germany Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 42: Germany Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 43: Germany 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

ITALY

Table 44: Italy Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 45: Italy Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 46: Italy 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

UNITED KINGDOM

Breakthrough Therapy (BT) Designation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 47: UK Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 48: UK Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 49: UK 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

REST OF EUROPE

Table 50: Rest of Europe Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 51: Rest of Europe Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 52: Rest of Europe 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

ASIA-PACIFIC

Breakthrough Therapy (BT) Designation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 53: Asia-Pacific Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 54: Asia-Pacific Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 55: Asia-Pacific 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

REST OF WORLD

Table 56: Rest of World Recent Past, Current & Future Analysis for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 57: Rest of World Historic Review for Breakthrough Therapy (BT) Designation by Application - Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 58: Rest of World 16-Year Perspective for Breakthrough Therapy (BT) Designation by Application - Percentage Breakdown of Value Sales for Oncology, Infectious Diseases, Rare Diseases, Pulmonary Diseases and Other Applications for the Years 2014, 2023 & 2030

IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

Abbvie
Acadia
Alexion
Amgen
AstraZeneca
BMS
Boehringer Ingelheim
Eisai
Eli Lilly
Exelixis

Quick Summary:

Global Breakthrough Therapy (BT) Designation Market to Reach $371.1 Billion by 2030

The U.S. Market is Estimated at $25.3 Billion, While China is Forecast to Grow at 19.2% CAGR

Select Competitors (Total 42 Featured) -

What's New?

What is the estimated value of the Global Market for Breakthrough Therapy (BT) Designation?

What is the growth rate of the Global Market for Breakthrough Therapy (BT) Designation?

What is the forecasted size of the Global Market for Breakthrough Therapy (BT) Designation?

Who are the key companies in the Global Market for Breakthrough Therapy (BT) Designation?

Table of Contents

Companies Mentioned

Related Topics

Related Reports

Drug Discovery Global Market Report 2023

Breakthrough Therapy Designation Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application

Orphan Drugs: Global Strategic Business Report

BT-11 Emerging Drug Insight and Market Forecast - 2032

Global Orphan Drugs Market by Disease Type (Gastrointestinal, Hematology, Infectious Diseases), Product Type (Biologic, Non-Biologic), Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-2030